We found that breast and ovarian cancers from the clinical trial #NCT01623349, which carry BRCA1/2 germline mutation, as well as germline mutation carriers from TCGA database had a high TMB as reported previously [29, 43, 44] but did not score high on overall immune activity and PD-L1 expression relative to non-carriers. This evidence concerns the gene BRCA1 and ovarian cancer.